Colon Cancer Clinical Trial
Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery
RATIONALE: The use of cholecalciferol and calcium carbonate may keep colon cancer from coming back in patients with colon cancer that has been removed by surgery.
PURPOSE: This randomized clinical trial is studying two different doses of cholecalciferol to compare how well they work when given together with calcium carbonate in treating patients with colon cancer that has been removed by surgery.
Compare the antiproliferative effects of 2 different doses of cholecalciferol (i.e., vitamin D3) in combination with calcium carbonate on the proliferative labeling index in patients with resected colon cancer.
Compare the effects of these doses on serum levels of 25-OH-D3, 1,25-OH-D3, 24,25-OH-D3, calcium, and parathyroid hormone in these patients.
Determine the safety of high-dose cholecalciferol in these patients over 2 years.
Compare the effects of these doses on several biological markers (i.e., cyclin D1, protein kinase C, vitamin D receptor, p21, and p27) in the rectal mucosa of these patients.
OUTLINE: This is a randomized, pilot study. Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive oral low-dose cholecalciferol once daily and oral calcium carbonate twice daily.
Arm II: Patients receive oral high-dose cholecalciferol once daily and calcium carbonate as in arm I.
Treatment in both arms continues for up to 2 years in the absence of disease progression or unacceptable toxicity. All patients undergo sigmoidoscopy or colonoscopy with 4 quadrant mucosal biopsies at baseline and after 6 months of study treatment. After their 6-month mucosal biopsy, patients in arm I switch to high-dose cholecalciferol as in arm II.
Patients undergo blood, urine, and tissue collection periodically during study for pharmacokinetic, pharmacodynamic, and/or histopathological analysis. Serum is collected monthly for 3 months and then once every 3 months to assess changes in serum levels of vitamin D and vitamin D metabolites (i.e., 1,25-OH-D3; 25-OH-D3; 24,25-OH-D3), as well as changes in calcium and parathyroid hormone, BUN, creatinine, electrolytes, and phosphorus levels. Urine is collected once every 3 months to assess changes in urine calcium and creatinine levels for hypercalciuria. Tissue biopsies of normal endorectal mucosa collected at baseline and after 6 months of study treatment are evaluated by IHC for proliferative index, vitamin D receptor staining, p21, p27, cyclin D1, and protein kinase C.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
History of colon cancer
Underwent resection and has been in clinical remission for ≥ 1 year
No inflammatory bowel disease
No familial adenomatous polyposis
ECOG performance status 0-2
Life expectancy > 1 year
No genitourinary stones within the past 5 years
No severe comorbid conditions, such as uncompensated heart failure or active uncontrolled infection
No history of hypercalcemia
No active colostomy
No contraindications to sigmoidoscopy or mucosal biopsies
PRIOR CONCURRENT THERAPY:
No prior rectal surgery or abdominoperineal resection
At least 1 month since prior vitamin D or calcium supplementation
Prior vitamin D supplemental intake ≤ 800 IU per day
At least 1 year since prior chemotherapy
No prior radiotherapy to the pelvis
No concurrent active anticoagulation
Patients who stop anticoagulation therapy at the time of mucosal biopsy are eligible
No other concurrent supplemental calcium or vitamin D
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Buffalo New York, 14263, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.